Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib for delaying progression to stage 3 type 1 diabetes in at-risk participants
jRCT2021250041Phase 3Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2026
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in diabetes mellitus type 1 (T1D) comparing Baricitinib with Placebo (2 arms). Started Jun 2026; status: recruiting.
02
Drugs
baricitinib
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on jRCT2021250041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2021250041.